SAIC Inc. (SAI)
The SAI share price is currently $16.03 or 75.1% off the 52-week high of $64.36. Its yield is 2.99%.
Up 34% over 12 months, SAIC Inc. has a market cap of $5.49 billion and is traded at a P/E of 12.90.
SAIC Inc. is a technology and engineering company, providing scientific, engineering, systems integration and technical services and solutions to all branches of the U.S. military and government agencies as well as foreign governments and customers in select commercial markets.
SAIC Inc. reported financial results for the second quarter of fiscal year 2014, which ended August 2, 2013, with $2.47 billion in revenue, down from $2.83 billion in the same quarter a year ago. For the quarter, the company reported $0.13 for diluted earnings per share, down from $0.32 in the same quarter a year ago. SAIC’s operating income of $75 million had dropped from $189 million in the same quarter a year ago.
Guru Action: Eight gurus currently hold shares and there is no recent insider trading.
As of June 30, 2013, four gurus made new buys and two gurus increased their positions by huge percentages. One guru sold out.
Jean-Marie Eveillard of First Eagle Investment Management is the new top Guru stakeholder, after making a new buy of 1,804,090 shares as of June 30, 2013. He bought the shares at an average price of $14.39, making a gain of 11.4%.
His current shares of 1,804,090 represent 0.53% of shares outstanding.
The biggest increase belongs to John Keeley. He increased his position by 3,357.38% in the second quarter. He bought 596,270 shares at an average price of $14.39, also gaining 11.4%.
Holding for four gaining quarters, Louis Moore Bacon sold out in the second quarter of 2013, selling 180,000 shares at an average price of $14.39, for a gain of 11.4%.
Tracking share price, revenue and net income since 2006:
AVEO Pharmaceuticals Inc. (NASDAQ:AVEO)
The AVEO share price is currently $2.09 or 81.0% off the 52-week high of $11.00. Its yield is 0.00%.
Down 80% over 12 months, AVEO Pharmaceuticals Inc. has a market cap of $109.03 million and is traded at a P/B of 1.00.
Incorporated in 2001, AVEO Pharmaceuticals Inc. is a cancer therapeutics company that discovers, develops and commercializes targeted cancer therapies. The company develops new drugs that target mechanisms known or believed to be involved in cancer.
The company reported second quarter 2013 financial results with a net loss of $31.9 million, up from its net loss of $29.5 million in the same quarter a year ago. The company reported revenue for the quarter at approximately $0.3 million, down from $1.9 million in the same quarter a year ago. The company spent $16.2 million in research and development (R&D) in the quarter, down from $21.5 million in the same quarter of 2012.
Guru Action: Four gurus currently hold shares and there is some insider trading.
As of June 30, 2013, Seth Klarman is the top Guru stakeholder, holding 3,829,350 shares or 7.34% of shares outstanding after he reduced his position by 21.9%. He sold 1,073,500 shares at an average price of $4.27, for a loss of 51.1%.
In seven losing quarters of holding, Klarman had a loss of 86% on 5,084,652 shares bought at an average price of $15.43 per share. He had a loss of 56% on 1,255,302 shares sold at an average price of $4.73 per share.
Chucky Royce made a new buy of 540,000 shares and Paul Tudor Jones made a new buy of 111,300 shares in the second quarter, both buying at an average price of $4.27, for a loss of 51%.
Tracking share price, revenue and net income:
If you are not a Premium Member, we invite you for a 7-day Free Trial.
GuruFocus Real Time Picks reports the stock purchases and sales that Gurus have made within the prior 2 weeks. The report time lag can be as short as 2 days after the date of the transaction. This feature is for Premium Members only.
Check out the GuruFocus special feature 52-week low screener to find the stocks hitting new lows but are still held by top investor Gurus and Insiders.
- Jean-Marie Eveillard Undervalued Stocks
- Jean-Marie Eveillard Top Growth Companies
- Jean-Marie Eveillard High Yield stocks, and
- Stocks that Jean-Marie Eveillard keeps buying
- John Keeley Undervalued Stocks
- John Keeley Top Growth Companies
- John Keeley High Yield stocks, and
- Stocks that John Keeley keeps buying